Neha Mehta-Shah, MD, MSCI explains how rational combinations to overcome CTCL treatment resistance keep running into added toxicity.
Neha Mehta-Shah, MD, MSCI
Advertisement
Neha Mehta-Shah, MD, MSCI, is an associate professor of medicine in the Division of Oncology at Washington University in St. Louis.
Articles by Neha Mehta-Shah, MD, MSCI
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Real-World Mogamulizumab Elicits Durable Responses in Pretreated Mycosis Fungoides and Sézary Syndrome
2
BI-1808 Shows Efficacy as Monotherapy and in Combination With Pembrolizumab in T-Cell Lymphomas
3
FDA Accepts Third RP1 BLA Resubmission With Nivolumab in Advanced Melanoma
4
From "Not Curable" to "May Be Curable": Joshua Richter, MD, on the New Reality of Multiple Myeloma
5